Compare AROW & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROW | CTMX |
|---|---|---|
| Founded | 1851 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.1M | 716.9M |
| IPO Year | 1995 | 2015 |
| Metric | AROW | CTMX |
|---|---|---|
| Price | $37.06 | $2.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $43.50 | $12.25 |
| AVG Volume (30 Days) | 59.6K | ★ 3.6M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 49.72 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $24.57 | N/A |
| Revenue Next Year | $16.41 | $1.24 |
| P/E Ratio | $25.08 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.91 | $2.60 |
| 52 Week High | $42.70 | $8.21 |
| Indicator | AROW | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 37.27 |
| Support Level | $35.58 | N/A |
| Resistance Level | $37.88 | $3.93 |
| Average True Range (ATR) | 0.74 | 0.18 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 11.99 | 17.11 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.